140 related articles for article (PubMed ID: 34462395)
1. Insulin-Like Growth Factor-1 Receptor Targeted Fluorescent Imaging for Gallbladder Cancer in Orthotopic Mouse Models.
Choi JH; Park JY
Gut Liver; 2022 Jul; 16(4):606-612. PubMed ID: 34462395
[TBL] [Abstract][Full Text] [Related]
2. Fluorescent-Antibody Targeting of Insulin-Like Growth Factor-1 Receptor Visualizes Metastatic Human Colon Cancer in Orthotopic Mouse Models.
Park JY; Murakami T; Lee JY; Zhang Y; Hoffman RM; Bouvet M
PLoS One; 2016; 11(1):e0146504. PubMed ID: 26731105
[TBL] [Abstract][Full Text] [Related]
3. Targeting the insulin growth factor-1 receptor with fluorescent antibodies enables high resolution imaging of human pancreatic cancer in orthotopic mouse models.
Park JY; Lee JY; Zhang Y; Hoffman RM; Bouvet M
Oncotarget; 2016 Apr; 7(14):18262-8. PubMed ID: 26919100
[TBL] [Abstract][Full Text] [Related]
4. EGFR-targeted fluorescent imaging using the da Vinci® Firefly™ camera for gallbladder cancer.
Choi JH; Kang CM; Park JY
World J Surg Oncol; 2022 Jun; 20(1):201. PubMed ID: 35701793
[TBL] [Abstract][Full Text] [Related]
5. ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer.
England CG; Kamkaew A; Im HJ; Valdovinos HF; Sun H; Hernandez R; Cho SY; Dunphy EJ; Lee DS; Barnhart TE; Cai W
Mol Pharm; 2016 Jun; 13(6):1958-66. PubMed ID: 27054683
[TBL] [Abstract][Full Text] [Related]
6. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies.
Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Oyen WJ; van der Graaf WT; van Laarhoven HW
Int J Cancer; 2013 Jul; 133(2):307-14. PubMed ID: 23335047
[TBL] [Abstract][Full Text] [Related]
8. PET imaging of insulin-like growth factor type 1 receptor expression with a 64Cu-labeled Affibody molecule.
Su X; Cheng K; Liu Y; Hu X; Meng S; Cheng Z
Amino Acids; 2015 Jul; 47(7):1409-19. PubMed ID: 25854877
[TBL] [Abstract][Full Text] [Related]
9. Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer.
Min HY; Yun HJ; Lee JS; Lee HJ; Cho J; Jang HJ; Park SH; Liu D; Oh SH; Lee JJ; Wistuba II; Lee HY
Mol Cancer; 2015 Jun; 14():113. PubMed ID: 26041671
[TBL] [Abstract][Full Text] [Related]
10. ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model.
Heskamp S; van Laarhoven HW; Molkenboer-Kuenen JD; Franssen GM; Versleijen-Jonkers YM; Oyen WJ; van der Graaf WT; Boerman OC
J Nucl Med; 2010 Oct; 51(10):1565-72. PubMed ID: 20847162
[TBL] [Abstract][Full Text] [Related]
11. XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer.
Schanzer JM; Wartha K; Moessner E; Hosse RJ; Moser S; Croasdale R; Trochanowska H; Shao C; Wang P; Shi L; Weinzierl T; Rieder N; Bacac M; Ries CH; Kettenberger H; Schlothauer T; Friess T; Umana P; Klein C
MAbs; 2016; 8(4):811-27. PubMed ID: 26984378
[TBL] [Abstract][Full Text] [Related]
12. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer.
Buck E; Gokhale PC; Koujak S; Brown E; Eyzaguirre A; Tao N; Rosenfeld-Franklin M; Lerner L; Chiu MI; Wild R; Epstein D; Pachter JA; Miglarese MR
Mol Cancer Ther; 2010 Oct; 9(10):2652-64. PubMed ID: 20924128
[TBL] [Abstract][Full Text] [Related]
13.
Solomon VR; Alizadeh E; Bernhard W; Hartimath SV; Hill W; Chekol R; Barreto KM; Geyer CR; Fonge H
Mol Pharm; 2019 Dec; 16(12):4807-4816. PubMed ID: 31518138
[TBL] [Abstract][Full Text] [Related]
14. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
[TBL] [Abstract][Full Text] [Related]
15. Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507.
Fleuren ED; Versleijen-Jonkers YM; van de Luijtgaarden AC; Molkenboer-Kuenen JD; Heskamp S; Roeffen MH; van Laarhoven HW; Houghton PJ; Oyen WJ; Boerman OC; van der Graaf WT
Clin Cancer Res; 2011 Dec; 17(24):7693-703. PubMed ID: 22038993
[TBL] [Abstract][Full Text] [Related]
16. Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTA-ZIGF1R:4551.
Tolmachev V; Malmberg J; Hofström C; Abrahmsén L; Bergman T; Sjöberg A; Sandström M; Gräslund T; Orlova A
J Nucl Med; 2012 Jan; 53(1):90-7. PubMed ID: 22173843
[TBL] [Abstract][Full Text] [Related]
17. Effects of insulin-like growth factor 1 receptor and its inhibitor AG1024 on the progress of lung cancer.
Wei YH; Tang HX; Liao YD; Fu SL; Xu LQ; Chen G; Zhang C; Ju S; Liu ZG; You LK; Yu L; Zhou S
J Huazhong Univ Sci Technolog Med Sci; 2015 Dec; 35(6):834-841. PubMed ID: 26670433
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the Antibody-Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors.
Akla B; Broussas M; Loukili N; Robert A; Beau-Larvor C; Malissard M; Boute N; Champion T; Haeuw JF; Beck A; Perez M; Dreyfus C; Pavlyuk M; Chetaille E; Corvaia N
Mol Cancer Ther; 2020 Jan; 19(1):168-177. PubMed ID: 31594825
[TBL] [Abstract][Full Text] [Related]
19. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.
Ulanet DB; Ludwig DL; Kahn CR; Hanahan D
Proc Natl Acad Sci U S A; 2010 Jun; 107(24):10791-8. PubMed ID: 20457905
[TBL] [Abstract][Full Text] [Related]
20. Dynamic and nuclear expression of PDGFRα and IGF-1R in alveolar Rhabdomyosarcoma.
Aslam MI; Hettmer S; Abraham J; Latocha D; Soundararajan A; Huang ET; Goros MW; Michalek JE; Wang S; Mansoor A; Druker BJ; Wagers AJ; Tyner JW; Keller C
Mol Cancer Res; 2013 Nov; 11(11):1303-13. PubMed ID: 23928059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
